SIC
AMED

SJS Investment Consulting’s Amedisys AMED Stock Holding History

SJS Investment Consulting’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$296 – 1639
2025
Q2 		$296 Sell
3
-2
-40% -$189 ﹤0.01% 1260
2025
Q1 		$464 Hold
5
– – ﹤0.01% 1273
2024
Q4 		$454 Sell
5
-1
-17% -$92 ﹤0.01% 1274
2024
Q3 		$580 Hold
6
– – ﹤0.01% 1272
2024
Q2 		$551 Hold
6
– – ﹤0.01% 1255
2024
Q1 		$553 Hold
6
– – ﹤0.01% 1249
2023
Q4 		$571 Hold
6
– – ﹤0.01% 1201
2023
Q3 		$561 Hold
6
– – ﹤0.01% 1176
2023
Q2 		$549 Buy
6
+3
+100% +$246 ﹤0.01% 1130
2023
Q1 		$221 Sell
3
-3
-50% -$260 ﹤0.01% 1339
2022
Q4 		$501 Buy
6
+2
+50% +$180 ﹤0.01% 1215
2022
Q3 		$0 Buy
+4
New +$477 ﹤0.01% 1020
2022
Q1 		$0 Buy
+1
New +$149 ﹤0.01% 691

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SJS Investment Consulting's AMED Position: Q3 2025 in Review

SJS Investment Consulting sold out of Amedisys (AMED) in Q3 2025, closing a stake of 3 shares — an estimated $296 sold.

SJS Investment Consulting first reported a position in AMED in Q1 2022 and held it in 13 quarters. The position peaked at $580 in Q3 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • SJS Investment Consulting reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • SJS Investment Consulting sold 3 Amedisys shares in Q3 2025, an estimated $296.
  • SJS Investment Consulting first reported a position in Amedisys in Q1 2022 and held it in 13 quarters.
  • SJS Investment Consulting's Amedisys position peaked at $580 in Q3 2024.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on SJS Investment Consulting's 13F filing for Q3 2025, filed 21 Oct 2025.